BOOM

Trending Searches

    SUPPORT
    BOOM

    Trending News

      • Fact Check 
        • Fast Check
        • Politics
        • Business
        • Entertainment
        • Social
        • Sports
        • World
      • Law
      • Explainers
      • News 
        • All News
      • Decode 
        • Impact
        • Scamcheck
        • Life
        • Voices
      • Media Buddhi 
        • Digital Buddhi
        • Senior Citizens
        • Videos
      • Web Stories
      • BOOM Research
      • BOOM Labs
      • Deepfake Tracker
      • Videos 
        • Facts Neeti
      • Home-icon
        Home
      • About Us-icon
        About Us
      • Authors-icon
        Authors
      • Team-icon
        Team
      • Careers-icon
        Careers
      • Internship-icon
        Internship
      • Contact Us-icon
        Contact Us
      • Methodology-icon
        Methodology
      • Correction Policy-icon
        Correction Policy
      • Non-Partnership Policy-icon
        Non-Partnership Policy
      • Cookie Policy-icon
        Cookie Policy
      • Grievance Redressal-icon
        Grievance Redressal
      • Republishing Guidelines-icon
        Republishing Guidelines
      • Fact Check-icon
        Fact Check
        Fast Check
        Politics
        Business
        Entertainment
        Social
        Sports
        World
      • Law-icon
        Law
      • Explainers-icon
        Explainers
      • News-icon
        News
        All News
      • Decode-icon
        Decode
        Impact
        Scamcheck
        Life
        Voices
      • Media Buddhi-icon
        Media Buddhi
        Digital Buddhi
        Senior Citizens
        Videos
      • Web Stories-icon
        Web Stories
      • BOOM Research-icon
        BOOM Research
      • BOOM Labs-icon
        BOOM Labs
      • Deepfake Tracker-icon
        Deepfake Tracker
      • Videos-icon
        Videos
        Facts Neeti
      Trending Tags
      TRENDING
      • #Operation Sindoor
      • #Pahalgam Terror Attack
      • #Narendra Modi
      • #Rahul Gandhi
      • #Waqf Amendment Bill
      • #Arvind Kejriwal
      • #Deepfake
      • #Artificial Intelligence
      • Home
      • Coronavirus
      • Centre To Buy 1 Cr Doses Of Zydus'...
      Coronavirus

      Centre To Buy 1 Cr Doses Of Zydus' COVID Vaccine At ₹265 Per Shot

      The vaccine is the only vaccine that is made of DNA plasmid and uses a needle-free applicator called Pharmajet instead of the traditional syringes

      By - Shachi Sutaria |
      Published -  9 Nov 2021 4:08 PM IST
    • Boomlive
      Centre To Buy 1 Cr Doses Of Zydus COVID Vaccine At ₹265 Per Shot

      The Government of India is set to procure one crore (ten million) doses of Zydus Cadila's Zy-CoV-D vaccine at a total of ₹265 per shot. This vaccine when introduced into the country's COVID-19 vaccine programme will be the first one that can be given to children above the age of 12 in the country.

      Ahmedabad-based Zydus has created the world's first COVID-19 vaccine using DNA plasmids. Another feature of this vaccine is that it will not be injected via needle syringes but will use a separate needle-free applicator that costs ₹93 per shot. This applicator, called PharmaJet helps in the administration of the vaccine intradermally (into the dermal layer of the skin) without any pain. It also reduces chances of undergoing needle-induced anxiety and any other post-vaccine side effects. One injector can give close to 20,000 shots.

      Also Read:Needle Phobia In Times Of Covid Vaccine: How To Cope With It?

      Zy-CoV-D is supposed to be administered in three doses within 28 days each. Each dose is further broken down into two separate doses on both arms. Along with the money and taxes levied through GST, the government is expected to pay ₹1,128 to Zydus for fully vaccinating an individual.

      While it received emergency use authorisation on August 20, there is no clarity on when the vaccine will be included in the country's COVID-19 immunisation programme. Its launch should be imminent as it is the only vaccine permitted in the country for inoculating those who are above the age of 12. Bharat Biotech's Covaxin has also received emergency use authorisation for vaccinating those who are in this age group as well as inoculating those between the ages of 5-12.

      The National Technical Advisory Group on Immunisation is yet to decide when the vaccine will be available for commercial use

      Earlier, Zydus wanted to sell its vaccine at close to ₹1,900. After repeated negotiations with the government, the pharmaceutical company agreed to reduce its prices. The Ministry currently procures Serum Institute of India's Covishield at ₹215 per shot and Bharat Biotech's Covaxin at ₹225 per shot.

      Neither the Centre nor the vaccine manufacturer have revealed how much the vaccine will cost when it is made available for the private health players across the country. People pay ₹780 for one dose of Covishield, ₹1410 for one shot of Covaxin, and ₹1145 for one shot of Russia's adenoviral Sputnik vaccine at private hospitals.

      Also Read:Centre Caps Covishield At ₹780, Covaxin At ₹1410 At Private Hospitals

      The DNA plasmid vaccine is 66 per cent effective against SARS-CoV-2 and the vaccine trials did not report any serious or severe adverse events among the recipients.


      Tags

      zydus cadilavaccine for childrenpharmajetneedle free vaccineDNA vaccineCOVID-19
      Read Full Article
      Next Story
      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker. Please reload after ad blocker is disabled.
      X

      Subscribe to BOOM Newsletters

      👉 No spam, no paywall — but verified insights.

      Please enter a Email Address
      Subscribe for free!

      Stay Ahead of Misinformation!

      Please enter a Email Address
      Subscribe Now🛡️ 100% Privacy Protected | No Spam, Just Facts
      By subscribing, you agree with the Terms & conditions and Privacy Policy connected to the offer

      Thank you for subscribing!

      You’re now part of the BOOM community.

      Or, Subscribe to receive latest news via email
      Subscribed Successfully...
      Copy HTMLHTML is copied!
      There's no data to copy!